Apixio vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 35)
Apixio logo

Apixio

EmergingHealthTech

Clinical NLP Analytics

Apixio uses NLP and machine learning to extract structured clinical insights from unstructured medical records, enabling more accurate risk adjustment and quality measurement for health plans.

AI VisibilityBeta
Overall Score
D35
Category Rank
#536 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
35
Gemini
39

About

Apixio's AI platform reads unstructured clinical documentation — physician notes, discharge summaries, operative reports, and scanned records — and extracts coded diagnoses, procedures, and clinical findings at scale using natural language processing and machine learning. Health plans and risk-bearing provider organizations use this extracted data to improve the accuracy of risk adjustment submissions to CMS, ensuring patients' true disease burden is captured in their risk scores.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

35
Overall Score
81
#536
Category Rank
#17
86
AI Consensus
71
stable
Trend
stable
40
ChatGPT
80
35
Perplexity
75
39
Gemini
77
40
Claude
86
41
Grok
85

Key Details

Category
Clinical NLP Analytics
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Apixio
Clinical NLP Analytics

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.